UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 1627, 2011

TIENS BIOTECH GROUP (USA), INC.

(Exact name of registrant as specified in its charter)


Delaware	001-32477	75-2926439
(State or other jurisdiction	(Commission File Number)	(I.R.S. Employer
of incorporation)		Identification Number)

No. 176, ~~Xinyuan~~Yuanquan ~~Rd.~~Road, Wuqing New -Tech Industrial Park, Tianjin, China ~~30170~~301700

(Address of principal executive offices)

Registrant’'s telephone number, including area code: (86)- 22-8213-~~7914~~7658

~~No.~~Not ~~6, Yuanquan Rd., Wuqing New Tech Industrial Park, Tianjin, China 301700~~applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o	Soliciting materials pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 25.0207 ~~Results~~Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition~~Vote of Security Holders.

On May 1627, 2011, Tiens Biotech Group (USA), Inc. (the “Company”) ~~issued~~held aits ~~press~~annual ~~release~~meeting ~~reporting~~of ~~the~~stockholders ~~Company’s~~(“Annual ~~financial~~Meeting”) ~~results~~to ~~for~~vote ~~the~~on ~~fiscal quarter ended March, 31, 2011. The full text of~~ the ~~press~~following ~~release is set forth in Exhibit 99.1 attached hereto.~~matters:

~~Item 9~~1.01 ~~Financial~~Election ~~Statements~~of ~~and Exhibits.~~Directors

~~(d) Exhibits~~All of the following five nominees were elected to the Company’s Board of Directors, in accordance with the voting results listed below, to serve for a term of one year, until the next Annual Meeting and until their successors have been duly elected and have qualified.

	Exhibit Number	Description
Nominee		For	Against	Abstain	Broker Non-Votes
	99.1	Press release, dated May 16, 2011.
Jinyuan Li		67,960,358	2,950	283,744	0
Yupeng Yan		67,963,112	196	283,744	0
Baolan Li		67,960,358	2,950	283,744	0
Socorro Quintero		67,963,262	46	283,744	0
Gilbert Raker		67,963,262	46	283,744	0

2. Ratification of the Company’s Independent Auditors

Stockholders ratified the appointment of Crowe Horwath LLP (“Crowe”) as independent auditors to audit the financial statements of the Company for the 2011 fiscal year, in accordance with the voting results listed below.

For		Against		Abstain		Broker Non-Votes
68,239,931		6,735		746		0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TIENS BIOTECH GROUP (USA), INC.
Date: May 16, 2011	By:	/s/ Jinyuan Li
Date: June 3, 2011	By:	/s/ Jinyuan Li
		Name: Jinyuan Li
		Title: Chief Executive Officer

Exhibits

	Exhibit Number	Description
	99.1	Press release, dated May 16, 2011.

Filing Compare · TIENS BIOTECH GROUP USA INC